Background. Culture-negative (CN) prosthetic joint infection (PJI) has not been well studied. We performed a retrospective cohort study to define the demographic characteristics and determine the outcome of patients with CN PJI.
Prosthetic joint infection ( PJI) involving a total hip athroplasty or total knee arthroplasty can occur in up to 5% of patients undergoing total joint replacement. Staphylococcus aureus and coagulase-negative Staphylococcus species account for close to 65% of PJIs [1] [2] [3] [4] [5] [6] [7] [8] [9] . We have observed a significant number of patients with PJI for whom aerobic and anaerobic cultures of periprosthetic tissue samples did not reveal the growth of any microorganisms. These patients received a diagnosis of PJI on the basis of the presence of periprosthetic purulence, acute pathology revealed by histopathologic examination of periprosthetic tissue samples, or a sinus tract communicating with the prosthesis. Although the outcome of microbiologically confirmed PJI has been well studied, the outcome and the demographic characteristics of patients with culture-negative (CN) PJI have not, to our knowledge, been previously published. This is, in part, because of the fact that patients with CN PJI are often excluded from published case series [10] [11] [12] Using strict case definitions for CN PJI and treatment failure, this retrospective cohort study was designed to estimate the probability of treatment failure among patients with CN PJI who were treated with various surgical modalities and to define variables that are associated with treatment failure.
PATIENTS AND METHODS

Study design.
In this retrospective case cohort study, patients were not randomized to any surgical or medical treatment modality. The treating physicians made treatment decisions. Patients were observed from the date of diagnosis of CN PJI until death, evident treatment failure, prosthesis removal, or loss to follow-up.
Study population. The study population consisted of patients with CN PJI who were seen at the Mayo Clinic (Rochester, MN) from 1 January 1990 through 31 December 1999. Only the first episode of CN PJI that was treated at our institution was included in the analysis. Cases of CN PJI were ascertained using the Mayo Clinic total joint registry [13] , master diagnostic index [14] , and microbiology laboratory data from the period 1990-1999. Some of the patients described in this study were included in previously published reports of PJI [3, 4] .
Definition of terms. CN PJI was diagnosed on the basis of the presence of purulence surrounding the prosthesis (as determined by the surgeon), histopathologic findings of acute inflammation of periprosthetic tissue samples that was consistent with infection (as determined by the pathologist), or a cutaneous sinus tract communicating with the prosthesis, in addition to there being no growth on aerobic and anaerobic cultures submitted to the clinical microbiology laboratory.
The following microbiologic methods were used for aerobic and anaerobic cultures of synovial fluid and tissue samples. Synovial fluid or tissue samples were inoculated in aliquots of 1-2 drops from a sterile pipet onto 5% sheep blood agar, onto chocolate blood agar, onto Centers for Disease Control and Prevention anaerobe 5% sheep blood agar, and into thioglycollate broth (BD Diagnostic Systems). Residual volumes of 0.5-3 mL were inoculated into a BACTEC Peds Plus/F bottle and incubated in a BACTEC 9240 instrument (BD Diagnostic Systems) for 5 days [15] . Tissue specimens were homogenized in 2 mL brain heart infusion broth for 1 min, and the homogenate was inoculated in the same manner as was the synovial fluid homogenate. Aerobic media and anaerobic media (BD Diagnostic Systems) were incubated at 35ЊC-37ЊC in 5%-7% CO 2 aerobically and anaerobically for 2 and 7 days, respectively. Thioglycollate broth was incubated for 5 days. Cloudy thioglycollate broth was subcultured.
Treatment failure was defined as having у2 cultures positive for the same microrganism from periprosthetic tissue or synovial fluid samples [1] , the presence of acute inflammation on histopathologic examination of periprosthetic tissue [2] , development of a sinus tract that communicated with the prosthesis [3] , presence of purulence in the joint space or surrounding the arthroplasty [4] , or clinical failure [5] . Clinical failure was defined as clinical, laboratory, and radiological findings suggestive of PJI at any time after the initial surgical procedure for CN PJI.
Prior antimicrobial use was defined as receipt of any antimicrobial therapy during the 3 months prior to the diagnosis of CN PJI. Joint age was defined as the time elapsed between joint arthroplasty and the diagnosis of PJI.
Statistical analysis. Data was summarized and reported using descriptive statistics. Categorical data were expressed as numbers and percentages, and parameters measured on a continuous scale were represented by the median, minimum, and maximum values. The survival free of treatment failure was estimated using the Kaplan-Meier survival method and reported with 95% CIs [16] . Differences in the survival function among groups that were defined by the levels of discrete prognostic factors were formally tested using the log-rank test. Cox proportional hazards modeling was used to assess hypothesized risk factors for treatment failure and to account for the correlation among multiple joints within a patient on the basis of a robust sandwich variance estimate. Hazard ratios (HRs) and corresponding 95% CIs and P values are reported from these models. Cox proportional hazards regression was also considered to investigate possible multivariable models but was restricted by the low number of treatment failures [17] . Alternatively, all prognostic factors considered in the univariate analysis were reassessed in models adjusted for age (a potential confounder of risk factor and treatment failure associations).
RESULTS
Study population.
Sixty first-time episodes of CN PJI occurred among 59 patients from 1 January 1990 through 31 December 1999 at Mayo Clinic. This accounted for 60 (7%) of 897 episodes of PJI encountered during the study period (table 1) . Twenty-eight (47%) of 60 first-time episodes of CN PJI occurred in female patients, and the median age at the time of diagnosis was 70 years (range, 36-87 years). Thirty-three (55%) of 60 CN PJI episodes were total knee arthroplasty infections. Of 60 episodes of CN PJI, rheumatoid arthritis was present in 12 (20%), and diabetes mellitus was present in 5 (8%). For 11 (18%) of 60 episodes, patients were receiving systemic steroid therapy at the time of diagnosis.
Clinical presentation. The median duration from prosthesis implantation to diagnosis of CN PJI was 1269 days (range, 6-8882 days). The median duration of symptoms prior to diagnosis was 103 days (range, 0-4511 days). A temperature of 138.2ЊC or a sinus tract were present in 13 (22%) and 6 (10%) of the 60 episodes, respectively. Histopathologic examination of periprosthetic tissue at the time of surgery revealed purulence and acute inflammation in 27 (45%) and 47 (78%) of the 60 episodes, respectively (table 2) .
Microbiologic examination. The median number of specimens per episode that were submitted to the clinical microbiology laboratory for aerobic and anaerobic cultures was 4 (range, [1] [2] [3] [4] [5] [6] [7] [8] . Fungal cultures of periprosthetic tissue specimens were performed in 35 episodes (median, 4 specimens per episode; range, 1-8 specimens per episode). Mycobacterial cultures of periprosthetic tissue specimens were performed in 32 episodes (median, 4 specimens per episode; range, 1-8 specimens per episode)
Prior use of antimicrobial therapy. Use of antimicrobial therapy during the 3 months prior to the diagnosis of CN PJI was present for 32 (53%) of 60 episodes. Of these 32 episodes, 14 (44%) were in patients receiving an antimicrobial at the time when the periprosthetic tissue culture result was determined. For 9 (28%), 2 (6%), and 7 (22%) of the 32 episodes, antimicrobial therapy was discontinued within 1 week, within 2 weeks, and 13 weeks after the diagnosis of CN PJI, respectively. The median duration of antimicrobial therapy prior to the diagnosis of CN PJI was 24.5 days (range, 1-1440 days).
The type of antimicrobial therapy that was administered prior to culture was b-lactams for 13 (41%) of 32 episodes and quinolones for 5 (16%) of 32 episodes. Other types of antimicrobial therapy (e.g., combination therapy, trimethoprimsulfamethoxazole, or macrolides) were used for 14 (44%) of 32 episodes. Medical therapy. The median duration of parenteral antimicrobial therapy for all episodes was 28 days (range, 2-88 days). Cephalosporins, the most commonly used antimicrobials, were used to treat 49 (82%) of 60 episodes; cefazolin therapy was used in 44 (90%) of these 49 episodes. Vancomycin was used to treat 7 (12%) of 60 episodes. Four (7%) of the 60 episodes were treated with other antimicrobial agents, including combination therapy with 2 classes of antimicrobials. The type of antimicrobial regimen chosen was carefully examined by the first author (E.F.B.) and compared with the antimicrobial regimen that was used prior to the diagnosis of CN PJI. Thirtyone patients received prior antimicrobial therapy and a course of parenteral antimicrobial therapy after the diagnosis of CN PJI. Only 20 (62%) of the 32 antimicrobials used had a concordant spectrum of activity between the antimicrobials used prior to and those used after the diagnosis of CN PJI diagnosis. Long-term oral antimicrobial suppression, commonly used in episodes treated with debridement and retention and 1-stage exchange, was used for 7 (12%) of 60 episodes; the median duration of such antimicrobial therapy was 1245 days (range, 245-3078 days).
Outcome and risk factors for treatment failure. The 5-year estimate of survival free of treatment failure among the 60 episodes was 82% (95% CI, 71%-93%) (figure 1). The rate of survival free of treatment failure was significantly different among the 3 types of surgical therapy ( ). The 5-year P ! .001 Kaplan-Meier estimates were 94% (95% CI, 85%-100%) for 2-stage exchange and 71% (95% CI, 44%-100%) for debridement and retention of components. Patients who underwent resection arthroplasty were observed for only 3 years, and the 3-year rate of survival free of failure among these patients was 51% (95% CI, 25%-82%). Patients who underwent resection arthroplasty were significantly more likely to experience treatment failure than were those who underwent 2-stage exchange (HR [adjusted for age ], 16.3; 95% CI, 3.08-86.5;
). P p .001 Although the difference was not statistically significant, patients who underwent debridement and retention had an increased risk of treatment failure by a factor of 5, compared with those who underwent 2-stage exchange (HR, 4.80; 95% CI, 0.88-27.3;
). Among 10 episodes in which treatment failure P p .07 occurred, 5 were CN PJI; 2 of these episodes were due to S. aureus infection, 1 was due to infection with coagulase-negative Staphylococcus species, and 1 was due to infection with to bhemolytic group B Streptococcus species. In the 1 episode classified as clinical failure, the patient underwent a permanent resection arthroplasty and, at the follow-up visit, was hospitalized with a draining wound. The patient was treated with a course of antimicrobial therapy. No additional follow-up data are available for this patient.
In addition to the type of surgical therapy, the absence of acute inflammation of periprosthetic tissue at the time of surgery was associated with a worse outcome. Patients without acute inflammation on histopathologic examination were 16 times more likely to experience treatment failure than were those with acute inflammation (HR [adjusted for age], 6.12; 95% CI, 1.76-21.35;
). In addition, insulin use reflected P ! .001 a trend for higher risk of treatment failure, with hazard increasing almost 4-fold for patients taking insulin, compared with those not taking insulin, with age held fixed (HR, 3.81; 95% CI, 0.89-16.31; ) P p .07 
DISCUSSION
Little information is available to guide clinicians regarding the optimal treatment of and outcome in patients with CN PJI. Previous studies of outcomes of PJI have often excluded CN cases from their analysis. At the Orthopedic Infectious Diseases service at the Mayo Clinic, we have observed a large number of cases of CN PJI in patients in whom a sinus tract or purulence was in communication with the prosthesis or acute inflammation was noted in periprosthetic tissue, and still, all aerobic and anaerobic cultures of periprosthetic tissue samples submitted to the clinical microbiology laboratory did not yield any microbial growth. This scenario was observed for 7% of PJI episodes treated at our institution during the study period. CN PJI often creates significant frustration for the infectious diseases specialist, the patient, and the orthopedic surgeon because of the uncertainties related to the optimal medical management and outcome. Occasionally, this situation also raises uncertainty regarding the presence of PJI.
We believe that the definition of CN PJI in our study provides confidence that this cohort represents patients with PJI because of the lack of alternative diagnoses for purulence surrounding the prosthesis, a sinus tract that communicates with the prosthesis, and the data regarding the specificity for PJI of acute inflammation seen on histopathologic examination of periprosthetic tissue [18] . This definition of PJI has also been used to determine the sensitivity and specificity of different culture techniques used to make a microbiologic diagnosis of PJI [19, 20] . Although noninfectious conditions, such as crystal-induced joint disease, rheumatologic diseases, and mechanical conditions, can sometimes mimic PJI, these diagnoses would seem very unlikely, given our definition of CN PJI.
Prior antimicrobial use has been shown by prior investigators to reduce the sensitivity of periprosthetic tissue cultures [19] . In our study, 53% of patients received an antimicrobial agent within 3 months before the diagnosis of CN PJI, and 23% were receiving an antimicrobial agent up to the time of periprosthetic tissue culture. If it can be done safely, we believe that discontinuing antimicrobial therapy 2-4 weeks prior to surgical intervention or culture seems advisable to improve the sensitivity of periprosthetic tissue cultures.
CN PJI in patients who did not receive antimicrobial therapy prior to the diagnosis of CN PJI could have been a result of a number of possibilities, including the inability of traditional tissue cultures (as processed in our clinical microbiology laboratory) to recover fastidious bacterial pathogens, bacterial pathogens encapsulated in biofilm, or unusual microorganisms (e.g., fungi or mycobacteria) that do not grow on routine aerobic or anaerobic media, as well as death of bacteria during specimen transportation or death of bacteria because of the release of locally delivered antibiotics at the time of prosthesis removal [15, [19] [20] [21] [22] [23] [24] . As recommended by participants in a recent workshop on musculoskeletal infection, our clinical microbiology laboratory archives tissue specimens for a short period of time, which allows clinicians to request necessary fungal and mycobacterial cultures in instances in which the aerobic and anaerobic cultures did not yield a pathogen and fungal and mycobacterial cultures were not initially requested by the orthopedic surgeon [20] .
We cannot, with any degree of certainty, exclude any of the above mentioned possibilities as potential etiologies for CN PJI. We believe, however, that the weight of evidence in this study would suggest that CN PJI may be due to biofilm producing microorganisms. Among the pieces of evidence favoring this hypothesis is that microorganisms in biofilm are known to be difficult to grow using traditional culturing techniques currently being used by clinical microbiology laboratories [19, 20] . Some investigators have suggested that obtaining multiple periprosthetic samples, prolonging incubation times, or performing culture or PCR on prosthesis ultrasonicate fluid samples improves the microbiologic diagnosis of biofilm microorganisms [19, 20] . Second, of the patients in our study for whom fungal and mycobacterial cultures were performed, none had cultures that yielded a microorganism. Third, none of the CN PJI treatment failures in this study were a result of infection with fungi or mycobacteria. Lastly, after medical and surgical management, assuming that the CN PJI was due to typical bacterial pathogens that cause PJI, the outcome of CN PJI was comparable with the outcome of PJI due to known microorganisms. Additional studies are warranted to confirm or refute this hypothesis.
The optimal medical and surgical therapy of patients with CN PJI is unknown. The overall outcome of episodes of CN PJI treated at our institution was not different from the reported outcomes of microbiologically confirmed episodes of PJI reported in the medical literature [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . This is important information for patients and physicians to keep in mind when similar situations are encountered.
Patients who underwent 2-stage exchange had an improved outcome, compared with those who received antimicrobial therapy alone and underwent permanent prosthesis removal for CN PJI. These data are consistent with outcome data from other cohorts of patients infected with known pathogens who underwent 2-stage exchange or were treated with antimicrobial therapy alone [5] [6] [7] [8] . The reason why patients who undergo 2-stage exchange have a better outcome than patients undergoing permanent prosthesis removal is less clear. Some possibilities for the difference in outcome between these 2 groups could include selection bias (because those patients undergoing 2-stage exchange may have fewer comorbidities that could lead to treatment failure) or that patients who undergo permanent prosthesis removal are not typically treated with local antimicrobial therapy, such as antibiotic-loaded polymethylmethacrylate-impregnated beads and spacers. This study was not designed to answer these questions.
With regard to optimal medical therapy, it is of interest that patients treated with a first-generation cephalosporin did not have worse outcomes than did patients treated with broadspectrum antimicrobial agents with activity against oxacillinresistant staphylococci or drug-resistant gram-negative organisms. It should be noted, however, that many of the patients who underwent 2-stage exchange would have received local antimicrobial therapy with vancomycin and/or an aminoglycoside. At least 1 study has suggested that local antimicrobial therapy may have some efficacy in the treatment of bone and joint infection [22] .
Limitations of this study include its retrospective study design, which allows for potential selection biases in comparisons of the outcomes in different medical and surgical therapy groups. In addition, we were unable to perform multivariate analyses that would identify independent risk factors for treatment failure because of sample size constraints.
In summary, the outcome of CN PJI is similar to the outcome of PJI due to known pathogens, and many episodes of CN PJI may be the result of prior antimicrobial therapy. We believe that the choice of systemic antimicrobial therapy of CN PJI should take into account the in vitro spectrum of activity of antimicrobial therapy administered within several weeks to a month prior to periprosthetic tissue culture, the in vitro spectrum of activity of any local antimicrobial therapy used by the orthopedic surgeon, local antimicrobial-resistance patterns (in addition to patient allergies), intolerances, and comorbidities. Optimal surgical therapy is dependent on a number of factors, including patient preference, stability of the prosthesis, prosthesis age, duration of symptoms, quality of the soft-tissue envelope surrounding the prosthesis, the type of prosthesis, and the operative risks for the patient undergoing the surgical procedure.
